When most people think about diabetes therapy they think of insulin or other pharmaceutical approaches. But new understanding of Type 2 diabetes has inspired one young company to develop a procedure aimed at the underlying digestive causes of the disease. Fractyl Laboratories (Waltham, Massachusetts) has raised a $40 million Series C financing round to support clinical evaluation of its Revita Duodenal Mucosal Resurfacing (DMR) procedure. The fully endoscopic procedure is designed to alter the inner surface of the duodenum and change how the body absorbs and processes sugar.
Read More
